Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Introduction: Hepatocellular carcinoma (HCC) has limited systemic therapy options when discovered at an advanced stage. Thus, there is a need for accessible and minimally invasive biomarkers of response to guide the selection of patients for treatment. This study investigated the biomarker value of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Yehia I., Duda, Dan G., Awiwi, Muhammad O., Lee, Sunyoung S., Altameemi, Lina, Xiao, Lianchun, Morris, Jeffrey S., Wolff, Robert A., Elsayes, Khaled M., Hatia, Rikita I., Qayyum, Aliya, Chamseddine, Shadi M., Rashid, Asif, Yao, James C., Mahvash, Armeen, Hassan, Manal M., Amin, Hesham M., Kaseb, Ahmed Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2022
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726202/
https://www.ncbi.nlm.nih.gov/pubmed/36473155
http://dx.doi.org/10.18632/oncotarget.28322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726202/
https://www.ncbi.nlm.nih.gov/pubmed/36473155
http://dx.doi.org/10.18632/oncotarget.28322

Ejemplares similares